Homepage | Lupus Science & Medicine
Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. An official journal of the Lupus Foundation of America (LFA), which is dedicated to advancing the science and medicine of lupus while offering support to ...
Thanoua etΔal Lupus Science Medicine 216e365 doi11136lupus21365 1 Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures Aikaterini Thanou , 1 Judith A James,1,2 Cristina Arriens , 1 Teresa Aberle,1 Eliza Chakravarty,1 Joseph Rawdon,1 Stavros Stavrakis,2 Joan T Merrill,1 Anca Askanase3 To cite: Thanou A, James JA, ...
Major infections in newly diagnosed systemic lupus …
Objective To evaluate the risk of major infections and the relationship between major infections and mortality in patients with newly diagnosed SLE. Methods A newly diagnosed (<3 months) hospitalised Systemic Lupus Inception Cohort (hSLIC) in our centre during 1 January 2013 and 1 November 2020 was established. All patients were followed up for at least 1 year or until death.
Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator’s Global Assessment <0.5 (0–3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. Conclusion The 2021 DORIS definition of ...
Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 …
Background and aims Several different versions of classification criteria, including the American College of Rheumatology (ACR)-1997, Systemic Lupus International Collaborating Clinics (SLICC)-2012 and European Alliance of Associations for Rheumatology (EULAR)/ACR-2019 classification criteria, have been launched in the past decades. The current study aimed to investigate the performance of ...
Clinical implications of discordance between anti-dsDNA …
Objective Anti-dsDNA antibodies (anti-dsDNA) are a component of all classification schemes in SLE and comprise one of the domains in validated activity indices. Anti-dsDNA is frequently measured commercially by an enzyme immunoassay (EIA) or Crithidia luciliae immunofluorescence test (CLIFT). To address the clinical impact of measuring these antibodies by two different assays, this study ...
Figure 4 Correlations of peripheral T lymphocyte phenotypes with disease activity and autoantibody titre in patients with SLE. (A) The frequency of CD4+CXCR5−PD1+ T cells was associated with SLEDAI- 2K scores. (B) The frequency of terminally differentiated CD8+ T cells was associated with the level of C4.
Clinical trial outcomes for SLE: what we have and what we need
The paradigm of drug approval in SLE currently relies on successful large phase III randomised controlled trials and a set of primary, secondary and additional end points. Taken together, these outcomes offer a nuanced understanding of the efficacy and safety of the investigational agent. In this review, we thoroughly examine the main outcomes used in SLE trials and highlight unmet ...
Current and future therapies for SLE: obstacles and …
Currently available treatments. Organ involvement and its related disease activity dictate the treatment for SLE. For constitutional symptoms and mild-to-moderate SLE, current guidelines recommend the use of antimalarial drugs, glucocorticosteroids (GCS), non-steroidal anti-inflammatory drugs (eg, for arthritis and serositis) and often immunosuppressive therapy for treating persistent disease ...
Efficacy and safety of telitacicept in patients with systemic lupus ...
Objective To examine the efficacy and safety of telitacicept in the treatment of patients with SLE in everyday clinical practice. Methods Seventy-two patients with active SLE who received telitacicept for more than 24 weeks at multiple centres in China between 2019 and 2022 were retrospectively identified. Twenty-one of these patients received 52 continuous weeks of …